Identification of four differentially methylated genes as prognostic signatures for stage I lung adenocarcinoma

被引:18
作者
Luo, Wei-Ming [1 ]
Wang, Zheng-Yu [2 ,3 ]
Zhang, Xin [4 ]
机构
[1] Shanghai Minhang Dist Canc Hosp, Dept Radiat Oncol, 106 Ruili Rd, Shanghai 200240, Peoples R China
[2] Xuzhou Med Univ, Affiliated Huaian Hosp, Dept Pharm, 62 South Huaihai Rd, Huaian, Peoples R China
[3] Second Peoples Hosp Huaian, 62 South Huaihai Rd, Huaian, Peoples R China
[4] Fourth Peoples Hosp Huaian, Dept Med Imaging, Huaian, Jiangsu, Peoples R China
关键词
Lung adenocarcinoma; Prognostic signature; DNA methylation; Survival analysis; DNA METHYLATION; CANCER; SURVIVAL; EXPRESSION; DATABASE; BIOMARKERS; DISCOVERY; MIGRATION; SERPINA5; VERSION;
D O I
10.1186/s12935-018-0547-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Lung adenocarcinoma (LUAD) is the main subtype of non-small cell lung cancer with a low survival prognosis. We aimed to generate a prognostic model for the postoperative recurrence of LUAD. Methods: The methylated DNA data of LUAD patients were downloaded from the Cancer Genome Atlas (TCGA). The differentially methylated genes were identified and protein-protein interacting network was constructed, with which prognostic signature of this cancer was generated. Survival and functional pathways analysis w used to evaluate the clustering ability of the prognostic signature. Results: We identified 151 differentially methylated genes related to relapse-free survival of patients with LUAD. Nine hub genes were identified in PPI network, with which 4 gene pair signature was selected as prognostic signature. The potential functions of 6 genes (JDP2, SERPINA5, PLG, SEMG2, RFX5, and POLR3B) in the 4-gene pair signature were enriched in intracellular protein synthesis and transportation. Conclusion: The four gene pair signature can predict the prognosis of patients with stage I LUAD. Our study provides a reference for patients with postoperative adjuvant therapy.
引用
收藏
页数:8
相关论文
共 44 条
[1]  
[Anonymous], GLOB 1 EST CANC INC
[2]  
[Anonymous], GLOBOCAN 2012 EST CA
[3]  
[Anonymous], INT J BIOL MARKERS
[4]  
[Anonymous], 2004, WEIGHTED K NEAREST N
[5]   Protein C inhibitor inhibits breast cancer cell growth, metastasis and angiogenesis independently of its protease inhibitory activity [J].
Asanuma, Kunihiro ;
Yoshikawa, Tomoaki ;
Hayashi, Tatsuya ;
Akita, Nobuyuki ;
Nakagawa, Norimi ;
Hamada, Yasuhiko ;
Nishioka, Junji ;
Kamada, Haruhiko ;
Gabazza, Esteban C. ;
Ido, Masaru ;
Uchida, Atsumasa ;
Suzuki, Koji .
INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (05) :955-965
[6]   Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].
Balch, CM ;
Buzaid, AC ;
Soong, SJ ;
Atkins, MB ;
Cascinelli, N ;
Coit, DG ;
Fleming, ID ;
Gershenwald, JE ;
Houghton, A ;
Kirkwood, JM ;
McMasters, KM ;
Mihm, MF ;
Morton, DL ;
Reintgen, DS ;
Ross, MI ;
Sober, A ;
Thompson, JA ;
Thompson, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648
[7]   On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer [J].
Bangma, Chris H. ;
van Schaik, Ron H. ;
Blijenberg, Bert G. ;
Roobol, Monique J. ;
Lilja, Hans ;
Stenman, Ulf-Hakan .
EUROPEAN JOURNAL OF CANCER, 2010, 46 (17) :3109-3119
[8]   CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].
BENJAMINI, Y ;
HOCHBERG, Y .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300
[9]   Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues [J].
Cao, Y ;
Becker, C ;
Lundwall, Å ;
Christensson, A ;
Gadaleanu, V ;
Lilja, H ;
Bjartell, A .
PROSTATE, 2003, 57 (03) :196-204
[10]  
Chansky Kari, 2010, Zhongguo Fei Ai Za Zhi, V13, P9, DOI 10.3779/j.issn.1009-3419.2010.01.02